Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients

Nephron Clin Pract. 2004;98(3):c93-100. doi: 10.1159/000080680.

Abstract

Background: Renal osteodystrophy is one of the major complications in patients with chronic renal failure. Large C-PTH fragments are secreted from the parathyroid glands and exert antagonistic actions against PTH-(1-84). The PTH-(1-84)/large C-PTH fragments ratio reflects both biosynthesis and processing of PTH; however the alteration of the ratio under vitamin D therapy has not been investigated.

Methods: Seventeen hemodialysis patients with intact PTH levels of >300 pg/ml were enrolled. Calcitriol or maxacalcitol were administered intravenously for 78 weeks. Intact PTH, PTH-(1-84), and the PTH-(1-84)/large C-PTH fragments ratio were measured at 0, 13, 26, 52 and 78 weeks.

Results: Intact PTH and PTH-(1-84) levels, which were 492.0 +/- 115.7 and 303.4 +/- 105.4 pg/ml, respectively, at baseline, significantly decreased at the end of the study to 268.9 +/- 121.9 (p < 0.0001) and 190.7 +/- 106.9 pg/ml (p = 0.0008), respectively. In contrast, large C-PTH fragments, which were 152.7 +/- 53.5 pg/ml at baseline, did not significantly change at 78 weeks (144.5 +/- 72.2 pg/ml, p = 0.7612). Consequently, the PTH-(1-84)/large C-PTH fragments ratio was significantly reduced from 2.25 +/- 1.31 to 1.47 +/- 0.89 (p = 0.0004).

Conclusion: The PTH-(1-84)/large C-PTH fragments ratio reflects the change of PTH biosynthesis, processing and secretion from the parathyroid glands, and it may be a beneficial marker to evaluate the overall biological PTH action and predict bone turnover status in hemodialysis patients under intravenous vitamin D therapy.

MeSH terms

  • Acid Phosphatase / blood
  • Alkaline Phosphatase / blood
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Remodeling / drug effects
  • Calcitriol / administration & dosage*
  • Calcitriol / analogs & derivatives
  • Calcium / blood
  • Chronic Kidney Disease-Mineral and Bone Disorder / blood
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy
  • Female
  • Humans
  • Injections, Intravenous
  • Isoenzymes / blood
  • Male
  • Middle Aged
  • Osteocalcin / blood
  • Parathyroid Hormone / analogs & derivatives*
  • Parathyroid Hormone / blood
  • Peptide Fragments / blood
  • Phosphorus / blood
  • Renal Dialysis*
  • Tartrate-Resistant Acid Phosphatase
  • Vitamins / administration & dosage*

Substances

  • Bone Density Conservation Agents
  • Isoenzymes
  • PTH protein, human
  • Parathyroid Hormone
  • Peptide Fragments
  • Vitamins
  • Osteocalcin
  • Phosphorus
  • Alkaline Phosphatase
  • Acid Phosphatase
  • Tartrate-Resistant Acid Phosphatase
  • Calcitriol
  • maxacalcitol
  • Calcium